Aptevo Therapeutics Inc.

NasdaqCM:APVO Stock Report

Market Cap: US$2.2m

Aptevo Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of APVO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1420.0284%
Hedge Funds25,2855.05%
Institutions31,5806.31%
General Public443,31988.6%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 4223.6%.


Top Shareholders

Top 25 shareholders own 11.39% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
5.05%
Hudson Bay Capital Management LP
25,285US$111.5k87.1%no data
4.42%
Armistice Capital LLC
22,128US$97.6k9.28%no data
0.6%
Citadel Advisors LLC
3,017US$13.3k0%no data
0.24%
Geode Capital Management, LLC
1,180US$5.2k126%no data
0.23%
Virtu Financial LLC, Asset Management Arm
1,134US$5.0k141%no data
0.2%
Renaissance Technologies LLC
988US$4.4k0%no data
0.15%
Hudson River Trading LLC, Asset Management Arm
759US$3.3k-8%no data
0.15%
Two Sigma Securities, LLC, Asset Management Arm
757US$3.3k0%no data
0.14%
Tower Research Capital Europe Limited
677US$3.0k224%no data
0.093%
Jane Street Group, LLC, Asset Management Arm
465US$2.1k0%no data
0.077%
Two Sigma Investments, LP
383US$1.7k0%no data
0.011%
The Vanguard Group, Inc.
56US$246.90%no data
0.0082%
Marvin White
41US$180.70%no data
0.0064%
Jeffrey Lamothe
32US$141.239.1%no data
0.0046%
BlackRock, Inc.
23US$101.50%no data
0.0044%
SoYoung Kwon
22US$97.137.5%no data
0.0032%
Daphne Taylor
16US$70.645.5%no data
0.0016%
Zsolt Harsanyi
8US$35.30%no data
0.0014%
Daniel Abdun-Nabi
7US$30.90%no data
0.0012%
John Niederhuber
6US$26.50%no data
0.001%
Morgan Stanley, Investment Banking and Brokerage Investments
5US$22.10%no data
0.001%
Barbara Kunz
5US$22.10%no data
0.001%
Grady Grant
5US$22.10%no data
0.0004%
Bank of America Corporation, Asset Management Arm
2US$8.8-50%no data
0.0002%
UBS Asset Management AG
1US$4.4-100%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 22:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aptevo Therapeutics Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangzhi LiLadenburg Thalmann & Company
Edward TenthoffPiper Sandler Companies
Jonathan AschoffRoth MKM